Kallie obtained her MChem degree from Newcastle University in 2020, with her final year research project focussing on DNA-encoded library synthesis in the Waring group. As part of her studies, she undertook an industrial placement year in the medicinal chemistry department at GlaxoSmithKline. After graduating, she completed a one-year internship in medicinal chemistry at Roche in Basel, Switzerland, before returning to Newcastle University to undertake her PhD developing small molecules to modulate neuroinflammation in the Harris group. She joined the Kawamura group soon after as a PDRA, where she investigates cyclic peptide ligand discovery for cancer targets.
Outside the lab, Kallie enjoys reading and crocheting.